Literature DB >> 16985902

Benign prostatic hyperplasia: an overview.

Claus G Roehrborn1.   

Abstract

Despite the deceptively simple description of benign prostatic hyperplasia (BPH), the actual relationship between BPH, lower urinary tract symptoms (LUTS), benign prostatic enlargement, and bladder outlet obstruction is complex and requires a solid understanding of the definitional issues involved. The etiology of BPH and LUTS is still poorly understood, but the hormonal hypothesis has many arguments in its favor. There are many medical and minimally invasive treatment options available for affected patients. In the intermediate and long term, minimally invasive treatment options are superior to medical therapy in terms of symptom and flow rate improvement; tissue ablative surgical treatment options are superior to both minimally invasive and medical therapy.

Entities:  

Year:  2005        PMID: 16985902      PMCID: PMC1477638     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  37 in total

1.  Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction.

Authors:  R C Rosen; J C Cappelleri; M D Smith; J Lipsky; B M Peña
Journal:  Int J Impot Res       Date:  1999-12       Impact factor: 2.896

Review 2.  Phytotherapy in the management of benign prostatic hyperplasia.

Authors:  F C Lowe
Journal:  Urology       Date:  2001-12       Impact factor: 2.649

Review 3.  The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms.

Authors:  D A Schwinn
Journal:  BJU Int       Date:  2001-09       Impact factor: 5.588

4.  Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia.

Authors:  B Djavan; C G Roehrborn; S Shariat; K Ghawidel; M Marberger
Journal:  J Urol       Date:  1999-01       Impact factor: 7.450

Review 5.  Population-based studies of the epidemiology of benign prostatic hyperplasia.

Authors:  C J Girman
Journal:  Br J Urol       Date:  1998-12

6.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Authors:  C G Roehrborn; P Boyle; A L Gould; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

7.  Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.

Authors:  C G Roehrborn; J D McConnell; M Lieber; S Kaplan; J Geller; G H Malek; R Castellanos; S Coffield; B Saltzman; M Resnick; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

8.  Test-retest variation of pressure flow parameters in men with bladder outlet obstruction.

Authors:  L M Eri; N Wessel; V Berge
Journal:  J Urol       Date:  2001-04       Impact factor: 7.450

9.  Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials.

Authors:  C G Roehrborn; M Malice; T J Cook; C J Girman
Journal:  Urology       Date:  2001-08       Impact factor: 2.649

10.  Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

Authors:  C G Roehrborn; J McConnell; J Bonilla; S Rosenblatt; P B Hudson; G H Malek; P F Schellhammer; R Bruskewitz; A M Matsumoto; L H Harrison; H A Fuselier; P Walsh; J Roy; G Andriole; M Resnick; J Waldstreicher
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

View more
  83 in total

1.  Prostatic osteopontin expression is associated with symptomatic benign prostatic hyperplasia.

Authors:  Petra Popovics; Wisam N Awadallah; Sarah E Kohrt; Thomas C Case; Nicole L Miller; Emily A Ricke; Wei Huang; Marisol Ramirez-Solano; Qi Liu; Chad M Vezina; Robert J Matusik; William A Ricke; Magdalena M Grabowska
Journal:  Prostate       Date:  2020-05-01       Impact factor: 4.104

Review 2.  Incontinence in the elderly, 'normal' ageing, or unaddressed pathology?

Authors:  William Gibson; Adrian Wagg
Journal:  Nat Rev Urol       Date:  2017-04-11       Impact factor: 14.432

Review 3.  Androgens and estrogens in benign prostatic hyperplasia: past, present and future.

Authors:  Tristan M Nicholson; William A Ricke
Journal:  Differentiation       Date:  2011-05-26       Impact factor: 3.880

4.  Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.

Authors:  Harold D Love; S Erin Booton; Braden E Boone; Joan P Breyer; Tatsuki Koyama; Monica P Revelo; Scott B Shappell; Jeffrey R Smith; Simon W Hayward
Journal:  PLoS One       Date:  2009-12-21       Impact factor: 3.240

Review 5.  Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia.

Authors:  Chris Olesovsky; Anil Kapoor
Journal:  Ther Adv Urol       Date:  2016-05-26

6.  Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing.

Authors:  Teresa T Liu; Allison C Rodgers; Tristan M Nicholson; Jill A Macoska; Paul C Marker; Chad M Vezina; Dale E Bjorling; Alejandro Roldan-Alzate; Diego Hernando; Granville L Lloyd; Timothy A Hacker; William A Ricke
Journal:  J Vis Exp       Date:  2019-08-14       Impact factor: 1.355

7.  Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Authors:  Samuel R Denmeade; Blair Egerdie; Gary Steinhoff; Rosemina Merchant; Ralph Abi-Habib; Peter Pommerville
Journal:  Eur Urol       Date:  2010-11-24       Impact factor: 20.096

8.  Holmium laser enucleation of the prostate in benign prostate hyperplasia patients with or without oral antithrombotic drugs: a meta-analysis.

Authors:  Xiaonan Zheng; Liao Peng; Dehong Cao; Xin Han; Hang Xu; Lu Yang; Jianzhong Ai; Qiang Wei
Journal:  Int Urol Nephrol       Date:  2019-09-07       Impact factor: 2.370

9.  Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

Authors:  Sigrid V Carlsson; Mari T Peltola; Daniel Sjoberg; Fritz H Schröder; Jonas Hugosson; Kim Pettersson; Peter T Scardino; Andrew J Vickers; Hans Lilja; Monique J Roobol
Journal:  BJU Int       Date:  2013-02-28       Impact factor: 5.588

10.  Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.

Authors:  Ferenc G Rick; Andrew Abi-Chaker; Luca Szalontay; Roberto Perez; Miklos Jaszberenyi; Arumugam R Jayakumar; Nagarajarao Shamaladevi; Karoly Szepeshazi; Irving Vidaurre; Gabor Halmos; Awtar Krishan; Norman L Block; Andrew V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.